A Study to Evaluate Etrasimod Treatment in Adolescents With Ulcerative Colitis
Status:
Not yet recruiting
Trial end date:
2028-10-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to determine the safety, efficacy, and pharmacokinetics (PK) of
etrasimod for the treatment of moderately to severely active ulcerative colitis in
adolescents (≥ 12 years up to < 18 years of age). Participants who will complete the total
52-week treatment period will have the opportunity to continue in a Long-Term Extension (LTE)
Period of up to 4 years (5 years after study enrollment), or until marketing authorization is
obtained in the participant's country, whichever comes first.